Floatz logo

Membrane-Bound Interleukin-21-Expanded Haploidentical Natural Killer Cells

Recurrent Acute Myeloid Leukemia

Sumithira VasuCell therapyPhase 1Dormant
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
89/ 100

Competitive context

685 Active assets in the Recurrent Acute Myeloid Leukemia cohort.

Asset / SponsorPhaseRating
Gemtuzumab
M.D. Anderson Cancer Center
Phase 4A
Cytosin-Arabinosid
Institute of Hematology & Blood Diseases Hospital, China
Phase 3BBB
AMSACRINE
University Hospital, Toulouse
Phase 4BBB
Posaconazole
AstraZeneca
Phase 4BBB
(+)-VINCRISTINE
Janssen Research & Development, LLC
Phase 3BBB

View all 50 →

Same molecule, other indications

Membrane-Bound Interleukin-21-Expanded Haploidentical Natural Killer Cells is also rated in:

disease related to hematopoietic stem cell transplantDormant
CC
Indicative ·
47 / 100
View asset →
myelodysplastic syndrome with excess blasts-2Dormant
CC
Indicative ·
47 / 100
View asset →
acute myeloid leukemiaDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →